Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Late Recurrences Beyond Five Years in Salivary Adenoid Cystic Carcinoma: Implications for Long-Term Surveillance.

OTO open·2026

Same author

Diagnostic delay in histiocytic neoplasms and its association with local resource deprivation.

Haematologica·2026

Same author

Class 3 MAP2K1 mutations are associated with frequent relapse and multiple treatment lines in multi-system Langerhans cell histiocytosis.

Blood advances·2026

Same author

Validation of MyHPVscore: A High-Performance Human Papillomavirus Circulating Tumor DNA Laboratory-Developed Test.

The Journal of molecular diagnostics : JMD·2026

Same author

Sustained remission after discontinuation of ALK inhibition in ALK-positive histiocytosis.

Blood cancer journal·2026

Same author

Consensus recommendations for malignant histiocytic neoplasms (histiocytic, Langerhans, and interdigitating dendritic cell sarcomas).

Blood·2026

Search research articles

Related Experiment Video

Updated: Jun 30, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Staging prognostic discussions about glioblastoma.

John T Fortunato^1,2,3, Amy Scharf⁴, Andrew G Shuman^5,6

¹Department of Neurology, University of Michigan, 1500 E Medical Center Drive, Ann Arbor, MI, 48109, USA. forjohn@med.umich.edu.

Journal of Neuro-Oncology

|January 9, 2026

Summary

Neuro-oncologists can improve glioblastoma prognosis communication through staged discussions. This approach balances ethical duties with patient understanding, enhancing the patient-physician relationship for better advance care planning.

Keywords:

Ethics Glioblastoma Prognosis Survivorship

More Related Videos

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

Related Experiment Videos

Last Updated: Jun 30, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

Area of Science:

Oncology
Neuro-oncology
Medical Ethics

Background:

Effective communication of prognostic information is crucial for glioblastoma patients.
Current practices in prognostic disclosure by neuro-oncologists are often ineffective and not routine.

Purpose of the Study:

To propose a novel framework for staged disclosure of prognostic information in glioblastoma.
To balance ethical obligations with effective patient communication and advance care planning.

Main Methods:

A narrative review of empirical data on prognostic disclosure in cancer and glioblastoma.
Development of a normative framework integrating clinical, ethical, and empirical insights.

Main Results:

A staged disclosure framework is proposed, discussing incurability and neurocognitive decline early.
Life expectancy estimations are deferred to a later visit, allowing for complete pathology results and trust-building.

Conclusions:

Staged prognostic discussions optimize communication for glioblastoma patients and families.
This approach balances oncologists' ethical duties and improves patient autonomy and advance care planning.
Further empirical research is needed to validate this staged disclosure method.